Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.About:
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.read more
Citations
More filters
Journal ArticleDOI
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Victor J. Dzau,Elliott M. Antman,Henry R. Black,David L. Hayes,JoAnn E. Manson,Jorge Plutzky,Jeffrey J. Popma,William G. Stevenson +7 more
TL;DR: A critical and comprehensive update of the current evidence for a CVD continuum based on the results of pathophysiological studies and the outcome of a broad range of clinical trials that have been performed in the past 15 years is presented.
Journal ArticleDOI
Validity of composite end points in clinical trials.
Victor M. Montori,Gaietà Permanyer-Miralda,Ignacio Ferreira-González,Jason W. Busse,Valeria Pacheco-Huergo,Dianne Bryant,Jordi Alonso,Elie A. Akl,Antònia Domingo-Salvany,Edward J Mills,Ping Wu,Holger J. Schünemann,Roman Jaeschke,Gordon H. Guyatt +13 more
TL;DR: In this article, a strategy to interpret the results of clinical trials when investigators measure the effect of treatment on an aggregate of end points of varying importance is provided.
Journal ArticleDOI
Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary.
Alan J. Garber,Yehuda Handelsman,George Grunberger,Daniel Einhorn,Martin J. Abrahamson,Joshua I. Barzilay,Lawrence Blonde,Michael A. Bush,Ralph A. DeFronzo,Jeffrey R. Garber,W. Timothy Garvey,Irl B. Hirsch,Paul S. Jellinger,Janet B. McGill,Jeffrey I. Mechanick,Leigh Perreault,Paul D. Rosenblit,Susan L. Samson,Guillermo E. Umpierrez +18 more
TL;DR: The objective of this study was to establish a baseline for the development of a strategy to manage the inflammatory bowel disease-related complications of type 2 diabetes using a proprotein convertase-like mechanism.
Journal ArticleDOI
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction Results of the CHARM Low-Left Ventricular Ejection Fraction Trials
James B. Young,Mark E. Dunlap,Marc A. Pfeffer,Jeffrey L. Probstfield,Alain Cohen-Solal,Rainer Dietz,Christopher B. Granger,Jaromír Hradec,J. Kuch,Robert S. McKelvie,John J.V. McMurray,Eric L. Michelson,Bertil Olofsson,Jan Östergren,Peter Held,Scott D. Solomon,Salim Yusuf,Karl Swedberg +17 more
TL;DR: Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF ≤40% when added to standard therapies including ACE inhibitors, β-blockers, and an aldosterone antagonist.
Journal ArticleDOI
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.
Fiona Turnbull,Bruce Neal,Marc A. Pfeffer,John B. Kostis,Charles S. Algert,Mark Woodward,John Chalmers,Alberto Zanchetti,Stephen MacMahon +8 more
TL;DR: There are similar blood pressure-dependent effects of ACEI and ARB for the risks of stroke, CHD and heart failure and for ACEI, but not ARB, there is evidence ofBlood pressure-independent effects on the risk of major coronary disease events.
References
More filters
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
An updated coronary risk profile. A statement for health professionals.
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more